A phase 1 clinical study of WT2725 in patients with advanced solid malignancies.
Latest Information Update: 07 Dec 2021
At a glance
- Drugs WT 2725 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sumitomo Dainippon Pharma
Most Recent Events
- 02 Nov 2015 New trial record